Off-Label Use of Upadacitinib for Treatment of Lichen Planus: A Narrative Review
Dermatology Practical & Conceptual · 30.04.2026 · 16 (2) · 6449
DOI: 10.5826/dpc.1602a6449 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 30.04.2026. Verfasst von Mark Gregory und 2 weiteren Autor:innen. Beteiligte Einrichtung: Wayne State University School of Medicine, Detroit, MI, USA. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Lichen planus (LP) is a chronic inflammatory disorder that primarily affects middle-aged adults and can involve the skin (cutaneous LP), mucous membranes (oral, esophageal, ocular, or vulvar LP), hair (lichen planopilaris, LPP), and nails. The exact cause of LP is not known, but the pathogenesis is thought to be multifactorial and involves T-cell mediated attack of skin and mucous membranes.
Objectives
The purpose of this review was to summarize the available reports regarding treatment of LP with the selective and reversible Janus kinase (JAK) 1 inhibitor upadacitinib.
Methods
PubMed and Google Scholar databases were queried using LP and upadacitinib terms with Boolean operators and assessed using the Oxford evidence criteria.
Results
Sixteen reports were included, comprising a 27 total of patients (19 females and eight males). Most cases were cutaneous LP (N=14, 51.8%) and LPP (N=6, 22.2%). Prior treatments included topical corticosteroids (N=21, 77.8%) and disease-modifying antirheumatic drugs (DMARDs) (N=14, 51.9%). The most common upadacitinib dosages were 15 mg once daily (N=19, 70.4%) and 30 mg once daily (N=5, 18.5%). Most patients achieved remission (N=21, 77.8%) after a median one month which lasted a median three months after treatment cessation or five months in patients who continued to receive treatment. Upadacitinib therapy had minimal, self-limited side effects (N=4, 14.8%).
Conclusions
Upadacitinib demonstrates potential as a tolerable and effective off-label treatment for LP. Larger studies are warranted to better define the safety and efficacy of upadacitinib in treating LP.
Autor:innen und Institutionen
- Wayne State University School of Medicine, Detroit, MI, USA.
- Dermatology, Wayne State University School of Medicine, Detroit, MI, USA.
Zitieren
APA
Gregory, M., Esfandiari, N., & Daveluy, S. (2026). Off-Label Use of Upadacitinib for Treatment of Lichen Planus: A Narrative Review. Dermatology Practical & Conceptual, 16(2), 6449. https://doi.org/10.5826/dpc.1602a6449
Vancouver
Gregory M, Esfandiari N, Daveluy S. Off-Label Use of Upadacitinib for Treatment of Lichen Planus: A Narrative Review. Dermatology Practical & Conceptual. 2026;16(2):6449. doi:10.5826/dpc.1602a6449
BibTeX
@article{Gregory2026,
author = {Gregory, Mark and Esfandiari, Negar and Daveluy, Steven},
title = {Off-Label Use of Upadacitinib for Treatment of Lichen Planus: A Narrative Review},
journal = {Dermatology Practical & Conceptual},
year = {2026},
volume = {16},
number = {2},
pages = {6449},
doi = {10.5826/dpc.1602a6449}
}
EUVIMED